Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology firm, will hold a conference call on May 13, 2021, at 4:30 PM ET to discuss its Q1 2021 financial results. The call will cover updates on eganelisib, an immuno-oncology drug under development aimed at reprogramming macrophages to combat immune suppression in cancer. Notable studies include MARIO-275 and MARIO-3, focusing on various combinations of eganelisib with other cancer therapies. A live webcast will be available on their website.
- Conducting multiple clinical studies (MARIO-275 and MARIO-3) for eganelisib, demonstrating ongoing research and potential progress in immuno-oncology.
- None.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Thursday, May 13th 2021 at 4:30pm ET to report its financial results for the first quarter of 2021.
Conference call & Webcast Details |
|||
Date: |
Thursday, May 13 |
||
Time: |
4:30 pm Eastern Time |
||
Webcast: |
|||
Toll Free: |
(877) 316-5293 |
||
International: |
(631) 291-4526 |
||
ID Number: |
9988449 |
||
A live webcast of the conference call can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005272/en/
FAQ
When is Infinity Pharmaceuticals' Q1 2021 earnings call?
What is eganelisib?
What are the key studies related to eganelisib?
How can I access the Infinity Pharmaceuticals conference call?
